1Hennekens CH, O′ Donnell CJ, Ridker PM. Current and future perspectives on antithrombotic therapy of acute myocardial infarction[J]. Eur Heart J, 1995, 16(Suppl D):2-9.
2Simpson E, Pilote L. Quality of life after acute myocardial infarction: a systematic review[J]. Can J Cardiol, 2003,19(5):507-511.
3Neuhaus KL, von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study(TAPS)[J]. JAm Coll Cardiol, 1992, 19(5):885 - 891.
4van de Loo A, Bode C. Hirudin in acute coronary syndromes[J]. Semin Thromb Hemost, 2002, 28(5):459 -466.
5Moustapha A, Anderson HV. Contemporary view of the acute coronary syndromes[J]. J Invasive Cardiol, 2003, 15(2) :71 - 79.
6Fox KA. r-Hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot study [J]. Eur Heart J, 1995, 16(Suppl D):28-32.
7Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris. A multicenter randomized angiographic trial[J]. Circulation, 1994, 89(4):1557- 1566.
8Choo JK, Young JJ, Kereiakes DJ. A guide to drug use during percutaneous coronary intervention [J]. Drugs,2002, 62(18) :2589-2601.
9Edwards J. Therapeutic potential of ischaemic preconditioning[J]. J Clin Pharmacol, 2000, 50:87 - 97.
10Hafner G, Rupprecht HJ, Luz M, et al. Recombinant hirudin as a periproeedural antithrombotic in coronary angioplasty for unstable angina pectoris[J]. Eur Heart J, 1996,17(8): 1207 - 1215.
